Nitrous oxide may interfere with the reconsolidation of drinking memories in hazardous drinkers in a prediction-error-dependent manner.
R K Das, K Walsh, J Hannaford, A I Lazzarino, Sunjeev K. Kamboj
European Neuropsychopharmacology July 1, 2018 DOI: 10.1016/j.euroneuro.2018.05.001 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 60 |
| Population | Hazardous drinkers |
| Intervention | Nitrous Oxide (N2O) |
| Dose | 50% N2O for 30 min |
| Duration | One week baseline, one week follow-up |
| Key findings | Nitrous oxide reduced drinking in a retrieval- and prediction-error-dependent manner when prediction error was actually experienced at retrieval. |
Abstract
Weakening drinking-related reward memories by blocking their reconsolidation is a potential novel strategy for treating alcohol use disorders. However, few viable pharmacological options exist for reconsolidation interference in humans. We therefore examined whether the NMDA receptor antagonising gas, Nitrous Oxide (N2O) could reduce drinking by preventing the post-retrieval restabilisation of alcohol memories in a group of hazardous drinkers. Critically, we focussed on whether prediction error (PE; a key determinant of reconsolidation) was experienced at retrieval. Sixty hazardous drinkers were randomised to one of three groups that retrieved alcohol memories either with negative PE (Retrieval + PE), no PE (Retrieval no PE) or non-alcohol memory retrieval with PE (No-retrieval +PE). All participants then inhaled 50% N2O for 30 min. The primary outcome was change in beer consumption and alcohol cue-driven urge to drink from the week preceding manipulation (baseline) to the week following manipulation (test). The manipulation did not affect drinking following the intended retrieval+/- PE conditions However, a manipulation check, using a measure of subjective surprise, revealed that the group-level manipulation did not achieve the intended differences in PE at retrieval. Assessment of outcomes according to whether alcohol-relevant PE was actually experienced at retrieval, showed N2O produced reductions in drinking in a retrieval and PE-dependent fashion. These preliminary findings highlight the importance of directly testing assumptions about memory reactivation procedures in reconsolidation research and suggest that N2O should be further investigated as a potential reconsolidation-blocking agent.
Citations in the library
Cited by 5
- Pharmacological modelling of dissociation and psychosis: an evaluation of the Clinician Administered Dissociative States Scale and Psychotomimetic States Inventory during nitrous oxide (‘laughing gas’)-induced anomalous states Psychopharmacology March 26, 2022
- Rapid antidepressant potential of nitrous oxide: current state and major questions. Molecular Psychiatry June 1, 2026
- Development and validation of a short-form (6-item) version of the clinician-administered dissociative states scale (CADSS-SF). European Journal of Psychotraumatology June 15, 2026
- Examining memory reconsolidation as a mechanism of nitrous oxide's antidepressant action. Neuropsychopharmacology March 1, 2025
- Rewarding Subjective Effects of the NMDAR Antagonist Nitrous Oxide (Laughing Gas) Are Moderated by Impulsivity and Depressive Symptoms in Healthy Volunteers. The International Journal of Neuropsychopharmacology July 23, 2021
Cites 7
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- Measurement of dissociative states with the Clinician‐Administered Dissociative States Scale (CADSS) Journal of Traumatic Stress 1998
- Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder JAMA Psychiatry April 16, 2014
- Nitrous oxide speeds the reduction of distressing intrusive memories in an experimental model of psychological trauma Psychological Medicine March 3, 2016
- Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discovery Today February 6, 2016
and 2 more in the library